Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
AstraZeneca
Dow
Baxter
McKesson

Last Updated: June 26, 2022

Investigational Drug Information for PSN-632,408


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug PSN-632,408?

PSN-632,408 is an investigational drug.

There have been 7 clinical trials for PSN-632,408. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2020.

The most common disease conditions in clinical trials are Colorectal Neoplasms, Neurotoxicity Syndromes, and Leukemia, Myelogenous, Chronic, BCR-ABL Positive. The leading clinical trial sponsors are Sanofi, Attikon Hospital, and National Cheng-Kung University Hospital.

There are sixty-four US patents protecting this investigational drug and seven hundred and thirty-seven international patents.

Recent Clinical Trials for PSN-632,408
TitleSponsorPhase
Topical Vancomycin Over Sternal Edge in Cardiac SurgeryNational Cheng-Kung University HospitalPhase 4
Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot StudyUniversity of AlbertaN/A
Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot StudyUniversity of TorontoN/A

See all PSN-632,408 clinical trials

Clinical Trial Summary for PSN-632,408

Top disease conditions for PSN-632,408
Top clinical trial sponsors for PSN-632,408

See all PSN-632,408 clinical trials

US Patents for PSN-632,408

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PSN-632,408 See Plans and Pricing Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk ELCELYX THERAPEUTICS, INC. (San Diego, CA) See Plans and Pricing
PSN-632,408 See Plans and Pricing Generation of muscle lineage cells and therapeutic uses thereof GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA) See Plans and Pricing
PSN-632,408 See Plans and Pricing Substituted piperidines having GPR119 agonistic activity DONG-A ST CO., LTD. (KR) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PSN-632,408

Drugname Country Document Number Estimated Expiration Related US Patent
PSN-632,408 Argentina AR091089 2031-01-07 See Plans and Pricing
PSN-632,408 Argentina AR091739 2031-01-07 See Plans and Pricing
PSN-632,408 Australia AU2011317140 2030-10-19 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
AstraZeneca
Dow
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.